CareDx, Inc. reported a total revenue of $380 million for the fiscal year ending December 31, 2025, marking a 14% increase from $334 million in 2024. The company's testing services revenue rose by 10% to $275 million, driven by a 14% increase in testing volume, which reached approximately 200,000 tests. However, the company experienced a net loss of $21.4 million in 2025, a significant decline from a net income of $52.5 million in the previous year. This shift was attributed to increased operating expenses, which surged by 40% to $410.6 million, largely due to higher sales and marketing costs and litigation expenses.
In terms of strategic developments, CareDx has focused on expanding its product offerings and enhancing its digital solutions. The company launched several new products and services, including pharmacy solutions and software aimed at improving patient management and operational efficiency for transplant centers. The patient and digital solutions segment saw a revenue increase of 31% to $57 million, while product revenue grew by 19% to $48 million. The company also reported a significant increase in its customer base, with its software solutions now utilized in over 170 transplant centers across the U.S.
Operationally, CareDx's workforce consisted of 765 employees as of December 31, 2025, with a notable increase in personnel dedicated to sales and marketing. The company has emphasized the importance of retaining skilled employees to support its growth strategy, which includes enhancing its research and development capabilities. The company’s cash, cash equivalents, and marketable securities totaled approximately $201.4 million at year-end, providing a solid liquidity position to support ongoing operations and potential future investments.
Looking ahead, CareDx aims to accelerate profitable growth by focusing on solutions selling at transplant centers and integrating its digital and patient solutions with laboratory products. The company is also committed to expanding its market presence internationally and enhancing its product offerings to address unmet medical needs in transplantation. However, the company faces challenges, including reliance on Medicare for a substantial portion of its revenue and potential changes in reimbursement policies that could impact its financial performance. CareDx's management remains optimistic about future growth, contingent on successful execution of its strategic initiatives and maintaining strong relationships with healthcare providers and payers.
About CareDx, Inc.
CareDx is a precision medicine company specializing in the discovery, development, and commercialization of high-value diagnostic solutions for transplant patients. Its core offerings include molecular diagnostic tests, digital patient management tools, and lab products that improve transplant outcomes. Serving transplant centers and healthcare providers primarily in the U.S. and Europe, CareDx leverages genomic technologies and data-driven solutions to enhance organ rejection detection, patient monitoring, and operational efficiency.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.